| Literature DB >> 28972117 |
Johan G Schnitzler1, Sophie J Bernelot Moens1, Feiko Tiessens1, Guido J Bakker1, Geesje M Dallinga-Thie1,2, Albert K Groen1,3, Max Nieuwdorp1,4,5,6, Erik S G Stroes1, Jeffrey Kroon7.
Abstract
The inflammatory profile of circulating monocytes is an important biomarker for atherosclerotic plaque vulnerability. Recent research revealed that peripheral lipid uptake by monocytes alters their phenotype toward an inflammatory state and this coincides with an increased lipid droplet (LD) content. Determination of lipid content of circulating monocytes is, however, not very well established. Based on Nile Red (NR) neutral LD imaging, using confocal microscopy and computational analysis, we developed NR Quantifier (NRQ), a novel quantification method to assess LD content in monocytes. Circulating monocytes were isolated from blood and used for the NR staining procedure. In monocytes stained with NR, we clearly distinguished, based on 3D imaging, phospholipids and exclusively intracellular neutral lipids. Next, we developed and validated NRQ, a semi-automated quantification program that detects alterations in lipid accumulation. NRQ was able to detect LD alterations after ex vivo exposure of isolated monocytes to freshly isolated LDL in a time- and dose-dependent fashion. Finally, we validated NRQ in patients with familial hypercholesterolemia and obese subjects in pre- and postprandial state. In conclusion, NRQ is a suitable tool to detect even small differences in neutral LD content in circulating monocytes using NR staining.Entities:
Keywords: cholesterol and trafficking; fluorescence and confocal imaging; lipid droplets; methods
Mesh:
Substances:
Year: 2017 PMID: 28972117 PMCID: PMC5665660 DOI: 10.1194/jlr.D073197
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922
Baseline characteristics of the clinical validation of NRQ
| Healthy Control (n = 3) | FH (n = 3) | Pre-meal | Post-meal | |||
| Age, years | 60 ± 10 | 61 ± 12 | 0.908 | 56 ± 12 | n/a | n/a |
| Gender, n, male (%) | 3 (100) | 3 (100) | n/a | 3 (100) | n/a | n/a |
| BMI | n/a | n/a | n/a | 38.3 ± 5.27 | n/a | n/a |
| Total cholesterol, mmol/l | 5.2 ± 0.9 | 8.8 ± 0.6 | 0.005 | 4.75 ± 0.11 | 4.97 ± 0.07 | 0.056 |
| LDL-C, mmol/l | 3.4 ± 0.6 | 6.9 ± 0.7 | 0.002 | n/a | n/a | n/a |
| HDL-C, mmol/l | 1.4 ± 0.3 | 1.0 ± 0.2 | 0.130 | n/a | n/a | n/a |
| TGs, mmol/l | 1.45 ± 0.3 | 1.78 ± 0.1 | 0.126 | 2.13 ± 0.29 | 3.27 ± 0.85 | 0.103 |
Values are n (%) or mean ± SD. HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; n/a, not applicable.
Fig. 1.LD detection by NR in human peripheral monocytes. A: NR-stained monocytes. Neutral lipids (green spheroids; left image) can be discriminated from phospholipids (red; middle image and right image; scale bars, 20 and 10 μm, respectively). B: Representative images of ORO-stained monocytes incubated with 50 μg/ml LDL for 1 h. The left image shows LDs by bright-field microscopy; LDs are indicated with white arrows. The right image was obtained by confocal microscopy. LDs are shown in green. C: NR-stained monocytes treated with 50 μg/ml LDL for 1 h. LDs are shown in green. Scale bar, 10 μm. D: The 3D images of monocytes (gray bodies shown on left images) untreated (upper images) and treated (lower images) for 1 h with 50 μg/ml LDL. LDs are shown in green.
Fig. 2.Processing steps and validation of the NRQ. A: Overview of processing steps of NRQ. B: Original image of the NR-stained monocytes. C: After converting it to grayscale, morphological opening of the grayscales and enhancement is created. D: Image (B) is then used to segment the cells with a region-based active contour method. E: Segmentation of the original image using a HSV color coding segmentation. F: After background correction using image (C), image (F) is obtained. Segmented lipid areas are then calculated with the aid of shape measurements (supplemental Fig. S3A–E). G: Counted areas are visualized with a blue circle, areas counted as two show an additional red circle, whereas areas counted as three are indicated with a green circle. The total amount of calculated LDs is shown in the gray bar; H, I: Pearson’s correlation between manual and NRQ quantification of LDs in circulating monocytes (H) and THP-1 cells (I) using 10–14 independent images.
Fig. 3.NR detection of LDs in monocytes in a time- and dose-dependent manner. A: Representative images of monocytes treated with 50 μg/ml LDL at different time points, as indicated. Scale bar, 10 μm. LDs and phospholipids are shown in green and red, respectively. B: Quantification of LD-positive monocytes after NR staining. C: Quantification of the amount of neutral LDs per positive monocyte after NR staining. D: Representative images for dose-dependent uptake of different concentrations of LDL, as indicated, for 1 h. Scale bar, 10 μm. LDs are shown in green, phospholipids in red. E, F: Quantification of dose dependency experiments in amount of LD-positive monocytes (E) and number of LDs (F) per LD-positive monocyte. P < 0.05 is considered significant. Data are shown as mean ± SEM for n = 5–7 independent experiments.
Fig. 4.Clinical validation of NRQ. A, B: LD-positive monocytes (A) and LDs per LD-positive monocyte (B) in FH patients. C, D: LD-positive monocytes (C) and LDs per LD-positive monocyte (D) before and 4 h after oral fat administration. P < 0.05 considered significant. Data are shown as mean ± SD for n = 3 patients per group.